CellCap Technologies Ltd, a Bacup, Lancashire-based UK-based medical company, has received a £75k investment from The North West Fund for Biomedical, managed by Spark Impact.
Formed in 2012 by CEO Damian Bond, CellCap has developed a new product to harvest stem cells from blood or adipose (fat) tissue, releasing them in a condition virtually identical to the state they are found naturally in the body.
The company, which will soon be relocating to Merseyside, intends to use the capital to evaluate its technology in two new laboratories to provide independent confirmation of the benefits and advantages of the product. The technology is also being investigated to create advancements in the detection of circulating tumour cells, microbes in biothreat, hospital, food or environmental areas, and the diagnosis of diseases such as Alzheimer’s.
FinSMEs
12/07/2012